Skip to content

A Study of an Recorded Variety of the Formula of Dispersing Mass and Nourishing Spirit for Advanced Breast Cancer with Anxiety

A Study of an Recorded Variety of the Formula of Dispersing Mass and Nourishing Spirit for Advanced Breast Cancer with Anxiety

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000379
Enrollment
Unknown
Registered
2025-02-21
Start date
2024-09-13
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced breast cancer combined with generalized anxiety disorder

Interventions

Experimental group:Standardized Western medicine treatment for breast cancer + Sanjie Yangshen Formula Granules(Formula for Dissipating Nodules and Nourishing the Spirit: Astragalus membranaceus, Epim
Control group:Standardized Western medicine treatment for breast cancer + placebo. For the placebo 5% of the original drug is used as the placebo.

Sponsors

Guang'anmen Hospital China Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1: Meets NCCN guidelines for diagnosis of advanced breast cancer 2: Meets diagnostic criteria for generalized anxiety disorder in Western medicine 3: Has not used anxiolytics or other psychotropic medications in the two months prior to enrollment 4: Aged 18-75 years

Exclusion criteria

Exclusion criteria: 1: Secondary anxiety caused by hyperthyroidism anxiety caused by drug overdose or withdrawal or anxiety caused by withdrawal from other bad habits; 2: Patients with unstable vital signs; 3: Patients with other malignant tumors; 4: Patients who are allergic to the drugs in this study; 5: Women who are pregnant lactating or trying to get pregnant 6: Patients with serious medical diseases such as heart brain and kidney diseases and infectious diseases 7: Patients with severe anxiety and depression such as suicidal tendencies; 8: Patients with glaucoma and epilepsy 9: Patients who are currently undergoing or have been in other clinical trials for no more than 3 months 10: Patients with poor compliance and inability to follow up regularly 11: Patients with a history of alcoholism and drug dependence.

Design outcomes

Primary

MeasureTime frame
Anxiety Level;Progression-free survival;

Secondary

MeasureTime frame
Quality of Life;

Countries

China

Contacts

Public ContactLU Wenping

Guang'anmen Hospital China Academy of Chinese Medical Sciences

lu_wenping@sina.com13811210423

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026